News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,119 Results
Type
Article (14380)
Company Profile (109)
Press Release (257628)
Multimedia
Podcasts (62)
Webinars (13)
Section
Business (88572)
Career Advice (467)
Deals (15441)
Drug Delivery (70)
Drug Development (36860)
Employer Resources (51)
FDA (6375)
Job Trends (6307)
News (151162)
Policy (14160)
Tag
Academia (444)
Accelerated approval (6)
Adcomms (7)
Allergies (56)
Alliances (23400)
ALS (50)
Alzheimer's disease (454)
Antibody-drug conjugate (ADC) (79)
Approvals (6485)
Artificial intelligence (168)
Autoimmune disease (24)
Automation (8)
Bankruptcy (150)
Best Places to Work (4432)
BIOSECURE Act (9)
Biosimilars (92)
Biotechnology (40)
Bladder cancer (33)
Brain cancer (27)
Breast cancer (133)
Cancer (1087)
Cardiovascular disease (124)
Career advice (417)
Career pathing (13)
CAR-T (43)
CDC (6)
Cell therapy (139)
Cervical cancer (8)
Clinical research (31776)
Collaboration (570)
Compensation (269)
Complete response letters (29)
COVID-19 (778)
CRISPR (37)
C-suite (317)
Cystic fibrosis (52)
Data (1378)
Denatured (18)
Depression (28)
Diabetes (115)
Diagnostics (1361)
Digital health (6)
Diversity (2)
Diversity, equity & inclusion (15)
Drug discovery (92)
Drug pricing (102)
Drug shortages (12)
Duchenne muscular dystrophy (71)
Earnings (33196)
Editorial (16)
Employer branding (4)
Employer resources (46)
Events (38573)
Executive appointments (513)
FDA (7275)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (348)
Gene editing (59)
Generative AI (13)
Gene therapy (145)
GLP-1 (416)
Government (1388)
Grass and pollen (4)
Guidances (159)
Healthcare (3587)
HIV (7)
Huntington's disease (6)
IgA nephropathy (28)
Immunology and inflammation (61)
Immuno-oncology (7)
Indications (32)
Infectious disease (831)
Inflammatory bowel disease (68)
Inflation Reduction Act (7)
Influenza (19)
Intellectual property (90)
Interviews (60)
IPO (5932)
IRA (33)
Job creations (2073)
Job search strategy (375)
Kidney cancer (9)
Labor market (26)
Layoffs (208)
Leadership (8)
Legal (3455)
Liver cancer (21)
Longevity (6)
Lung cancer (159)
Lymphoma (95)
Machine learning (9)
Management (17)
Manufacturing (318)
MASH (59)
Medical device (1305)
Medtech (1308)
Mergers & acquisitions (9855)
Metabolic disorders (375)
Multiple sclerosis (39)
NASH (14)
Neurodegenerative disease (57)
Neuropsychiatric disorders (17)
Neuroscience (775)
NextGen: Class of 2025 (1608)
Non-profit (603)
Now hiring (17)
Obesity (195)
Opinion (142)
Ovarian cancer (33)
Pain (92)
Pancreatic cancer (39)
Parkinson's disease (64)
Partnered (9)
Patents (188)
Patient recruitment (87)
Peanut (12)
People (29627)
Pharmaceutical (65)
Pharmacy benefit managers (15)
Phase I (8303)
Phase II (13415)
Phase III (12087)
Pipeline (1086)
Policy (121)
Postmarket research (1403)
Preclinical (3315)
Press Release (25)
Prostate cancer (75)
Psychedelics (14)
Radiopharmaceuticals (126)
Rare diseases (271)
Real estate (2667)
Recruiting (18)
Regulatory (10666)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (3)
RNA editing (5)
RSV (16)
Schizophrenia (58)
Series A (63)
Series B (34)
Service/supplier (3)
Sickle cell disease (40)
Special edition (10)
Spinal muscular atrophy (77)
Sponsored (8)
Startups (1659)
State (2)
Stomach cancer (3)
Supply chain (42)
Tariffs (66)
The Weekly (42)
Vaccines (215)
Venture capital (25)
Weight loss (126)
Women's health (13)
Worklife (4)
Date
Today (28)
Last 7 days (252)
Last 30 days (892)
Last 365 days (10859)
2025 (9088)
2024 (12559)
2023 (14315)
2022 (19630)
2021 (20167)
2020 (19113)
2019 (14946)
2018 (11788)
2017 (14017)
2016 (13215)
2015 (15578)
2014 (12448)
2013 (10596)
2012 (11403)
2011 (11927)
2010 (10889)
Location
Africa (323)
Alabama (17)
Alaska (1)
Arizona (69)
Arkansas (3)
Asia (20654)
Australia (2662)
California (2694)
Canada (1298)
China (437)
Colorado (113)
Connecticut (111)
Delaware (103)
Europe (40500)
Florida (517)
Georgia (55)
Hawaii (1)
Idaho (9)
Illinois (290)
India (33)
Indiana (208)
Iowa (1)
Japan (187)
Kansas (72)
Kentucky (18)
Louisiana (3)
Maine (2)
Maryland (377)
Massachusetts (2260)
Michigan (41)
Minnesota (142)
Mississippi (1)
Missouri (29)
Montana (8)
Nebraska (6)
Nevada (16)
New Hampshire (6)
New Jersey (1196)
New Mexico (7)
New York (769)
North Carolina (529)
North Dakota (2)
Northern California (1182)
Ohio (69)
Oklahoma (5)
Oregon (18)
Pennsylvania (639)
Puerto Rico (10)
Rhode Island (15)
South America (510)
South Carolina (8)
Southern California (1153)
Tennessee (47)
Texas (381)
United States (10922)
Utah (52)
Virginia (135)
Washington D.C. (41)
Washington State (185)
West Virginia (1)
Wisconsin (29)
272,119 Results for "kite pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
With more than $1.5 billion on the line, Gilead looks to bolster its CAR T portfolio.
October 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors
September 23, 2025
·
3 min read
Press Releases
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
October 14, 2025
·
18 min read
Layoffs
Appia, Former Kite Cell Therapy Collaborator, Shuts Down
Appia Bio’s shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.
August 26, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Business
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
Cellares today announced that Kite , a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle.
June 27, 2024
·
2 min read
Business
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL).
June 3, 2024
·
19 min read
Biotech Beach
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
June 3, 2024
·
14 min read
Biotech Bay
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Arcellx, Inc. and Kite, a Gilead Company, announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.
May 9, 2024
·
9 min read
Biotech Bay
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.
May 9, 2024
·
9 min read
1 of 27,212
Next
